相关实验视频
Updated: Jun 19, 2026

06:50
Extraction and Analysis of Taiwanese Green Propolis
Published on: January 7, 2019
糖尿病患者在应对健康问题时使用草药产品:来自土耳其的横截面研究
Elif Doğar1, Hatice Tuba Akbayram2, Yıldız Büyükdereli Atadağ1
1Department of Family Medicine, Faculty of Medicine, Gaziantep University, 27600, Gaziantep, Turkey.
Internal and emergency medicine
|April 14, 2025
概括
大约30%的2型糖尿病患者使用草本产品来控制血糖,体重,胆固醇和血压. 高等教育与使用量增加相关,而脏病与使用量较低相关.
科学领域:
- 内分泌学 在内分泌学.
- 药理学是指药理学,即药理学是指药理学.
- 公共卫生 公共卫生
背景情况:
- 2型糖尿病 (T2DM) 是一个全球性的健康问题.
- 治疗T2DM通常需要改变生活方式和药物治疗.
- 补充和替代医学,包括草药产品,经常被慢性病患者使用.
研究的目的:
- 调查在T2DM患者中使用草药产品的流行率.
- 为了确定使用草本产品的原因.
- 探索与这种人群中草药产品消费相关的因素.
主要方法:
- 在糖尿病门诊所对280名T2DM患者进行了横截面研究.
- 面对面的采访是使用覆盖人口统计,疾病状况和草药产品使用的问卷进行的.
- 使用统计分析来确定变量之间的关联.
主要成果:
- 30.4%的T2DM患者报告使用草药产品.
- 高等教育水平与草药产品使用增加有显著的关联 (p=0.014).
- 患有病的患者使用草药产品的频率低于没有病的患者 (p=0.045).
- 使用的主要原因包括血糖调节 (58.8%),减肥 (17.6%),胆固醇管理 (14.1%),血压控制 (9.4%).
- 通常使用的草药包括橄叶,肉和黑种子用于血糖控制;核桃汁和用于高脂血症;大和用于高血压;和绿茶用于体重控制.
- 在草药产品使用和糖尿病持续时间,胰岛素使用或HbA1c水平之间没有发现显著的关系.
结论:
- 很大一部分T2DM患者在各种健康问题上使用草药产品.
- 教育程度和病的存在是影响使用草药决定的关键因素.
- 了解这些模式对于医疗保健提供者提供全面的患者护理和指导至关重要.
相关概念视频
Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
